469total views of outputs
792total downloads of outputs
37views of outputs this month
44downloads of outputs this month
I am Professor of Biomedical Science, I established and directing the Biomedical Science programme and leading the Cancer Biology and Therapy research group. I joined LSBU in 2018 having previously worked as Research Associate Professor at the University of Arizona College-of-Medicine-Phoenix and the Institute of Molecular Medicine at Phoenix Children's Hospital. I led research on precision medicine in paediatric leukemia. I was a senior researcher at Karolinska Institutet, Sweden and a postdoctoral fellow at the National Cancer Institute, USA working on novel functions of the IGF-1R in cancer and stem cells, and on in vivo functions of cell cycle regulators.
My research interests are the identification of molecular drivers and novel targeted therapeutics in cancer, the identification of hypoxia-induced drug resistance in acute myeloid leukemia, and identification of novel functional partners for the nuclear IGF-1R in cancer. The goal of my research is to advance our understanding of the mechanisms underlying cancer development and progression, and cancer drug resistance. I have published over 40 articles in the field.
I have recently established and leading the Cancer Biology and Therapy research group that includes 3 PhD scientists with focus in cancer molecular biology, molecular docking, epigenetics, and bioinformatics, 3 postgraduate students and one part time technical assistant. We are hosting national and international placement students and interns.
The mission of my research group is to contribute to the discoveries that lead to combat cancer, such as understanding the mechanisms of cancer development, metastasis, and the discovery of novel “druggable” targets to apply in refractory/resistant cancer types. We are working on fostering interdisciplinary academic and industrial collaborations and to train the next generation of cancer researchers. With a generous fund from LSBU I was able to equip the lab with instruments for high-throughput drug screening, high content imaging, flow cytometry, Real-time QPCR and basic molecular biology instruments.
Through grants funded by the Children Cancer Network, Phoenix Children’s Leadership Circle grant, USA, and the European Commission and the Swedish Research Links, EU, my projects were on the investigation of how hypoxia alters drug response in acute myeloid leukemia, the development of a 3D bone-marrow microenvironment mimicking cell culture model to better predict drug response in leukemia, and on novel functional interactions of the nuclear form of IGF-1 receptor in cancer. I apply a variety of technologies including next-generation sequencing, functional proteomics, in vitro 3D cell culture models.
I am currently the director of studies for 3 PhD students working on the interaction of IGF-1R with Immune checkpoint inhibition in cancer, the nuclear IGF-1R in cancer, and the microbiome in health and disease. The last topic is in collaboration with Weil-Cornel Qatar University.
My external activities include editorial board memberships; I am Associate editor for Frontiers in Cell and Developmental Biology, Cell Growth Section (IF 6.081) and a member of the Editorial boards of the Journal of Experimental & Clinical Cancer Research (IF:12.658) and Cancers (IF 6.102). I am also an external PhD examiner for international universities, and an international assessor for academic promotions.
Biomedical Sciences - BSc (Hons)
BSc (Hons) Bioscience 2022/23
Postgraduate Research Supervision
|Mrs Mavra Manzar||Doctoral Research Project||PhD|
|Miss Banu Baarthi Godfri||Doctoral Research Project||PhD|
|Mrs Christine Jenner Gaskell||Doctoral Research Project||PhD|
University of Heidelberg, Germany
University of Alexandria, Egypt
Institute of Biomedical Science
|Proposal||Project||Role||Funder||Status||Status last updated|
|Acrylamide exposure and risk assessment in the UK||Acrylamide exposure and risk assessment in the UK||Co-Investigator||Biotechnology and Biological Sciences Research Council (BBSRC)||OPEN In preparation||Mar 2023|
|Eiman KTP- LADDER THERAPEUTICS LIMITED||Eiman KTP- LADDER THERAPEUTICS LIMITED||Principal Investigator||Knowledge Transfer Partnership||OPEN In preparation||Dec 2022|
Cancers is a peer-reviewed, open access journal of oncology, published semimonthly online by MDPI. The Irish Association for Cancer Research (IACR), Signal Transduction Society (STS) and Spanish Association for Cancer Research (ASEICA) are affiliated with Cancers and their members receive a discount on the article processing charges.
Exopolysaccharide-peptide complex from oyster mushroom (Pleurotus ostreatus) protects against hepatotoxicity in rats
Abdel-Monem, NM, El-Saadani, MA, Daba, AS, Saleh, SR and Aleem, E (2020). Exopolysaccharide-peptide complex from oyster mushroom (Pleurotus ostreatus) protects against hepatotoxicity in rats. Biochemistry and Biophysics Reports. 24, pp. 100852-100852. https://doi.org/10.1016/j.bbrep.2020.100852
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis
Azorsa, DO, Lee, DW, Wai, DH, Bista, R, Patel, AR, Aleem, E, Henry, MM and Arceci, RJ (2018). Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis. Pediatric Blood and Cancer. 65 (9), pp. e27237-e27237. https://doi.org/10.1002/pbc.27237
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
Bista, R, Lee, DW, Pepper, OB, Azorsa, DO, Arceci, RJ and Aleem, E (2017). Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. Journal of Experimental & Clinical Cancer Research. 36 (22). https://doi.org/10.1186/s13046-017-0493-5
Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage
Waraky, A, Lin, Y, Warsito, D, Haglund, F, Aleem, E and Larsson, O (2017). Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage. Journal of Biological Chemistry. 292 (44), pp. 18227-18239. https://doi.org/10.1074/jbc.M117.781492
Downregulation of IGF-1 receptor occurs after hepatic linage commitment during hepatocyte differentiation from human embryonic stem cells
Waraky, A, Aleem, E and Larsson, O (2016). Downregulation of IGF-1 receptor occurs after hepatic linage commitment during hepatocyte differentiation from human embryonic stem cells. Biochemical and Biophysical Research Communications. 478 (4), pp. 1575-1581. https://doi.org/10.1016/j.bbrc.2016.08.157
Targeting cell cycle regulators in hematologic malignancies
Aleem, E. and Arceci, R.J. (2015). Targeting cell cycle regulators in hematologic malignancies. Frontiers in Cell and Developmental Biology. 3 (APR), pp. 16-. https://doi.org/10.3389/fcell.2015.00016
Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism
Waraky, A., Akopyan, K., Parrow, V., Strömberg, T., Axelson, M., Abrahmsén, L., Lindqvist, A., Larsson, O. and Aleem, E. (2014). Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism. Oncotarget. 5 (18), pp. 8379-8392. https://doi.org/10.18632/oncotarget.2292
Nanoparticle mediated cancer cell therapy: Basic science to clinical applications
Verma, J., Warsame, C., Seenivasagam, R.K., Kumar, N., Abdel Aleem, E. and Goel, S. (2023). Nanoparticle mediated cancer cell therapy: Basic science to clinical applications. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-023-10086-2